Frontiers in Endocrinology (Dec 2022)
The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension
Abstract
No abstracts available.Keywords
Frontiers in Endocrinology (Dec 2022)